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CRISPR-Cas9 Editing of Human
Histone Deubiquitinase Gene USP16
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Line THP-1
Iveta Gažová1†‡, Lucas Lefevre1†‡, Stephen J. Bush1†‡, Rocio Rojo1†‡, David A. Hume2‡,
Andreas Lengeling1†‡ and Kim M. Summers1,2*‡
1 The Roslin Institute, University of Edinburgh, Easter Bush, United Kingdom, 2 Mater Research Institute - University of
Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
USP16 is a histone deubiquitinase which facilitates G2/M transition during the cell
cycle, regulates DNA damage repair and contributes to inducible gene expression. We
mutated the USP16 gene in a high differentiation clone of the acute monocytic leukemia
cell line THP-1 using the CRISPR-Cas9 system and generated four homozygous
knockout clones. All were able to proliferate and to differentiate in response to phorbol
ester (PMA) treatment. One line was highly proliferative prior to PMA treatment and shut
down proliferation upon differentiation, like wild type. Three clones showed sustained
expression of the progenitor cell marker MYB, indicating that differentiation had not
completely blocked proliferation in these clones. Network analysis of transcriptomic
differences among wild type, heterozygotes and homozygotes showed clusters of
genes that were up- or down-regulated after differentiation in all cell lines. Prior to
PMA treatment, the homozygous clones had lower levels than wild type of genes
relating to metabolism and mitochondria, including SRPRB, encoding an interaction
partner of USP16. There was also apparent loss of interferon signaling. In contrast,
a number of genes were up-regulated in the homozygous cells compared to wild type
at baseline, including other deubiquitinases (USP12, BAP1, and MYSM1). However,
three homozygotes failed to fully induce USP3 during differentiation. Other network
clusters showed effects prior to or after differentiation in the homozygous clones. Thus
the removal of USP16 affected the transcriptome of the cells, although all these lines
were able to survive, which suggests that the functions attributed to USP16 may be
redundant. Our analysis indicates that the leukemic line can adapt to the extreme
selection pressure applied by the loss of USP16, and the harsh conditions of the
gene editing and selection protocol, through different compensatory pathways. Similar
selection pressures occur during the evolution of a cancer in vivo, and our results can
be seen as a case study in leukemic cell adaptation. USP16 has been considered a
target for cancer chemotherapy, but our results suggest that treatment would select for
escape mutants that are resistant to USP16 inhibitors.
Keywords: histone deubiquitinases, epigenetic modifications, THP-1 cell line, genome editing, macrophage,
monocyte, USP16 gene
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 May 2021 | Volume 9 | Article 679544
fcell-09-679544 May 26, 2021 Time: 8:27 # 2
Gažová et al. USP16 in THP-1 Leukemia Cells
INTRODUCTION
The development of a tumorigenic lineage from healthy cells is
usually associated with a wide range of genetic changes, including
point mutations, small and large deletions and insertions (indels)
and chromosomal rearrangements (Vogelstein et al., 2013).
A high level of genomic instability in cancer cells allows for
novel forms of effector molecules to be produced, but also
imposes a genetic load of potentially detrimental mutations.
Cancer lineages are heterogeneous with many diverse sublineages
arising over time (Heppner, 1984; Vogelstein et al., 2013), and
these are subjected to intensive selection pressure as the tumor
evolves (Fortunato et al., 2017).
One form of modification in cancer lines is alteration in
the epigenetic status of the cells. Addition or removal of
repressive marks on histone molecules is a major mechanism
for altering gene expression, and a number of genes encoding
enzymes associated with histone modifications have been
identified as tumor suppressors, for example, the histone
deubiquitinase BAP1 (Abdel-Rahman et al., 2011) and the
histone demethylase KDM6A (Ler et al., 2017). Ubiquitination
of the lysine at position 119 in histone 2A (H2AK119)
blocks transcription by preventing RNA polymerase from
traveling along the DNA template (Lanzuolo and Orlando,
2012). During transcriptional activation, H2A deubiquitinases
remove ubiquitin from H2AK119 (Abdel-Wahab et al., 2012).
A small number of these enzymes have been identified,
among as many as 100 deubiquitinases in the human genome
(Komander et al., 2009; Belle and Nijnik, 2014). These are
six ubiquitin specific proteases (USPs; USP3, USP12, USP16,
USP21, USP22, and USP46), one ubiquitin C-terminal hydrolase
(BAP1) and one Zn2+ metalloprotease (MYSM1) (Chen et al.,
2015). The present study focused on the role of the histone
deubiquitinase USP16.
USP16 (originally named UBP-M; Cai et al., 1999) is
an 823 amino acid protein containing two domains; a zinc
finger, ubiquitin-binding type domain (ZnF UBP domain;
also called BUZ domain), which is also found in histone
deacetylase 6 (HDAC6); and a catalytic site in the C19 family
cysteine peptidase domain (Figure 1A). The ZnF UBP domain
contains three zinc-binding sites consisting of 12 residues
(Pai et al., 2007), which facilitate protein-protein and DNA-
protein interactions, and the cysteine peptidase domain acts as
a ubiquitin carboxyl-terminal hydrolase (Rawlings and Barrett,
1994). The protein was initially localized in cytoplasm (Cai
et al., 1999). Subsequently it was found that USP16 functions
as a homotetramer and is actively exported from the nucleus
during interphase (Xu et al., 2013). At the onset of mitosis
USP16 is phosphorylated at serine 552, by cyclin dependent
kinase 1 (CDK1) (Xu et al., 2013) and localizes to the nucleus,
where it is required for G2/M progression. The function of
USP16 in mitosis is to deubiquitinate and therefore activate polo
like kinase 1 (PLK1), which is needed for proper chromosome
alignment, without which cell cycle progression is blocked at G2
(Joo et al., 2007).
USP16 can also act as a regulator of DNA damage repair.
DNA double strand break damage induces H2A ubiquitination
at the site of damage. The levels of USP16 mRNA increase
directly after DNA damage. After the break is repaired, the
ubiquitin is removed by USP16 with the help of HERC2 (HECT
and RLD domain containing E3 ubiquitin protein ligase 2)
(Zhang et al., 2014). Over-expression of USP16 resulted in
decreased ubiquitination of H2A immediately after the damage,
while down-regulation resulted in increased and prolonged
ubiquitination and failure to resolve the break (Zhang et al.,
2014). The net result of either change was to reduce the
cell’s ability to repair DNA damage, either because the initial
ubiquitination of H2A at the site of the break was suppressed
(over-expression of USP16) or because the ubiquitin could not
then be removed after the repair (down-regulation) (Zhang
et al., 2014). There are examples where USP16 was down-
regulated or mutated in leukemias and other human cancers,
such as lung adenocarcinoma and hepatocellular carcinoma,
which might contribute to the inability of cancer cells to
resolve the DNA repair process (Fernandez et al., 2004; Gelsi-
Boyer et al., 2008; Qian et al., 2016), but these are rare
and the gene is ubiquitously expressed (data from FANTOM5
project1) and only rarely mutated (data from The Cancer
Genome Atlas2).
USP16 may also contribute to inducible gene expression.
USP16 was shown to be bound to promoter regions of various
genes on all chromosomes of embryonic stem cells (ESC), and
this was correlated with low H2A ubiquitination levels and high
gene expression (Yang et al., 2014). USP16 was also identified
to bind to active genes and promoters and take part in a shift
of mouse B-cells from quiescent to active state (Frangini et al.,
2013). In addition, USP16 regulates developmental Hox genes in
Xenopus laevis (Joo et al., 2007).
Homozygous knockout of the Usp16 gene (Usp16−/−) in
mouse is embryonically lethal. Defects in development were
found as early as 7.5 days after conception (E7.5) (Yang
et al., 2014). USP16 catalytic function was required for ESC
differentiation, but not ESC viability (Yang et al., 2014). Knock
down of USP16 in human HeLa cells caused slow cell growth
rates, as there was a sharp decrease in cells in phase G2/M of the
cell cycle (Joo et al., 2007). There was also a decrease in HOX
gene expression. In Usp16 conditional bone marrow knockout
mice, the hematopoietic stem cells were reduced in maturity
and lineage commitment and there were fewer mature cells in
peripheral blood (Gu et al., 2016).
USP16 is located on human chromosome 21, which is trisomic
in Down syndrome (Adorno et al., 2013). In mice triplication
of Usp16 was associated with accelerated senescence, consistent
with the early aging phenomena in patients with Down syndrome
(Adorno et al., 2013). Consequences of overexpression of Usp16
in mice included reduction of hematopoietic stem cells and
their self-renewal ability, cellular defects owing to increased
removal of H2A ubiquitin and decreased proliferation (Adorno
et al., 2013). Patients with Down syndrome also have increased
incidence of leukemia and decreased rate of solid tumors
(Mateos et al., 2015). A human Down syndrome cell line with
1https://fantom.gsc.riken.jp/zenbu/, accessed April 2021
2https://www.cancer.gov/tcga, accessed April 2021
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FIGURE 1 | Sanger sequencing of exon 4 of USP16 clones. (A) Structure of the human USP16 gene and protein. Blue – ZnF UBP domain; yellow – ubiquitin specific
protease (USP) domains; red bars – cysteine (left) and histidine (right) boxes of the C19 family peptidase domain. Asparagine at position 200 and cysteine at position
205 are key residues of the cysteine box; histidine at position 758 and aspartate at position 798 are key residues of the histidine box. The peptidase unit extends
from residue 141 to the C terminus at residue 823. The USP domains are members of the C19 family of cysteine peptidases. Drawn from data in Jones et al. (2013),
Rawlings and Barrett (2013) and the MEROPS database at https://www.ebi.ac.uk/merops/index.shtml (Rawlings et al., 2018). (B) Sequence of USP16 in edited
clones. Upper panel shows the wild type, middle panel shows a heterozygote and lower panel shows a homozygous edited clone. The site of the insertion is
indicated by the arrow and the amino acid codons of the wild type allele are shown above the sequence traces. All three founder heterozygous clones had the same
insertion of adenine (A; green trace) in one allele. The four homozygous USP16−/− clones had the same insertion of one additional adenine, on both alleles. The
nucleotide sequence before and after the insert was identical to wild type. (C) Translation of edited USP16 in homozygous clones by the ExPaSy tool (single letter
code). Insertion of the single nucleotide causes a frame shift, which introduces multiple stop codons in the translated sequence. The insert is present in the middle of
the zinc finger domain, in codon 91 for the amino acid alanine (pictured here framed by yellow box). Ten codons later, translation would be terminated by an in frame
stop codon. Met indicates potential start codons (amino acid methionine), and highlighted sequences show open reading frames. The first gray sequence up to the
yellow box is the correct amino acid sequence.
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a triplicated USP16 gene had decreased DNA damage response
(Zhang et al., 2014).
These results show that USP16 has three functions: cell
cycle progression (Xu et al., 2013), DNA damage repair
(Zhang et al., 2014) and gene activation by removal of H2A
ubiquitin (Yang et al., 2014). Disruption of each of these activities
could contribute to generation and progression of leukemia.
Here we report the creation of a loss of function mutation
in the USP16 gene using CRISPR-Cas9 technology in the
THP-1 human acute monocytic leukemia (AML) cell line.
The THP-1 cell line was isolated in 1980 from a 1-year
old boy suffering from AML. The cells resemble human
monocytes (Tsuchiya et al., 1980) but can be induced to
differentiate into macrophage-like cells by administration of
phorbol myristate acetate (PMA) (Tsuchiya et al., 1982).
PMA initially inhibits cell growth prior to differentiation,
by up-regulation of the cyclin-dependent kinase CDKN1A;
this in turn inhibits the activating phosphorylation of CDK2
(Traore et al., 2005). In the parent THP-1 line available from
the American Type Culture Collection (ATCC R© TIB-202TM),
around 50% of cells become adherent in response to PMA,
indicating that there is considerable phenotypic heterogeneity
(see Supplementary Figure 1 in Suzuki et al., 2009). To
enable a detailed study of the transcriptomic response to
PMA, the FANTOM consortium isolated a clonal line that
was highly responsive to PMA and uniformly differentiated
into a macrophage like state (Suzuki et al., 2009; Gazova
et al., 2020). The karyotype of the clonal line was established
by microarray-based comparative genomic hybridization to be
46XY, with minimal chromosomal aberrations (deletions at 6p,
12p, 17p, and on the X chromosome) (Adati et al., 2009).
The THP-1 cells are also predisposed to mutations in tumor
suppressor genes (for example TP53 and PTEN) and MLL fusions
(Adati et al., 2009).
We report the knockout of USP16 in four homozygous cell
lines derived from the high differentiation clone of THP-1.
We observed heterogeneity amongst the homozygous knockout
lines and examined their transcriptomic profiles to understand
whether these cells have evolved mechanisms to compensate for
the impact of the USP16 mutation.
MATERIALS AND METHODS
THP-1 Cell Line and Differentiation Assay
THP-1 cells (high differentiation clone 5, from FANTOM4
consortium, passage number 8, provided by Dr. Mark Barnett,
The Roslin Institute, United Kingdom) were cultured as
described previously (Gazova et al., 2020). The day before
the start of the differentiation assay, cells were counted by
hemocytometer and between 3 × 106 and 5 × 106 cells were
pelleted and resuspended in 10 ml fresh medium. THP-1 cells
were then differentiated by adding 30 ng/ml (48.6 nM) phorbol
12-myristate 13-acetate (PMA; P1585, Sigma-Aldrich) in DMSO.
The cells were plated on a Sterilin plate (without tissue culture
treatment of the plastic), and after 24 h of differentiation, the cells
were lifted off by flushing with a blunt-end needle syringe.
CRISPR-Cas9 Editing of USP16 in THP-1
Cells
The CRISPR sequence guide was designed using an online
website tool3, and selected based upon base chemistry
and possible off-target effects. Information about human
USP16 protein and gene structures was taken from the
Ensembl database4 (Yates et al., 2016). Information was
correct as of January 2021, based on transcript USP16-
201 (ENST00000334352.8). The guide was designed to
target exon 5 (5′-TGGCGTCAGATAGTGCTTCA-3′,
score 79). In silico translation of the altered USP16 DNA
exonic sequence into protein was provided by the online
ExPaSy tool5. Transcription start site (TSS) information
was taken from the FANTOM5 database (Forrest et al.,
2014) visualized on the ZENBU hg19 genome viewer6
(Severin et al., 2014). The oligonucleotides were ordered
through Sigma-Aldrich (0.025 µmol, DST purification)
(Ran et al., 2013).
Annealing and phosphorylation of the CRISPR guides
followed the protocol of Andersson-Rolf et al. (2016). The
phosphorylated and annealed oligonucleotides were diluted
1:200 and then cloned into a plasmid vector containing the
Streptococcus pyogenes Cas9 open reading frame sequence and
a GFP reporter gene (pX458 from Addgene, plasmid#48138,
kindly provided by Dr. Peter Hohenstein, The Roslin Institute)
in one step. Cutting and ligation was done by adding together
100 ng of pX458, 2 µl of the diluted annealed oligonucleotide,
2 µl of 10X T4 ligase buffer with 10mM ATP (NEB, Ipswich,
MA, United States), 1 µl of BbsI restriction endonuclease
(10 U/µl, NEB), 0.5 µl of ligase from Quick Ligation kit
(NEB) made up to 20 µl with water. The mixture was
incubated for 6 cycles of 37◦C for 5 min and 21◦C for
5 min. The plasmid with sgRNA sequence was treated using
the Plasmid Safe Exonuclease kit (Epicentre, Madison, WI,
United States) which digests any residual linear DNA, following
manufacturer’s instructions.
DH5α strain E. coli bacteria were then transformed with
the plasmid using a heat shock at 42◦C and the bacteria
were streaked on an ampicillin plate (100 µg/ml ampicillin
in LB (Lysogeny Broth) agar). Two colonies per plate were
selected and grown overnight in 5 ml LB with 100 µg/ml
ampicillin. To assess the presence of the appropriate insert,
plasmid DNA was extracted using the Qiagen MiniPrep
kit according to manufacturer’s instructions (Qiagen,
Hilden, Germany). The sequence was validated by chain
termination sequencing using U6 FWD primer at Edinburgh
Genomics (University of Edinburgh, United Kingdom).
A large scale preparation of plasmid DNA was then
made using the Endo-free Maxi Prep (Qiagen) according
to manufacturer’s instructions. It was important to use
endotoxin-free (Endo-free) reagents to avoid activating the
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prep-prepared plasmid was again verified by sequencing at
Edinburgh Genomics.
Nucleofection of CRISPR-Cas9 Plasmids
Into THP-1 Cells
THP-1 cells were transfected using the 4D Nucleofector kit
(Lonza, Cologne, Germany), with a Lonza protocol optimized for
THP-1 cells. 1 × 106 THP-1 cells per sample were centrifuged
at 400 g for 5 mins, the pellet resuspended in 100 µl of SG 4D
Nucleofector solution with added supplement (SG Cell line 4D
Nucleofector solution X kit, Lonza). 0.5 µg of DNA per sample
of Endotoxin-free plasmid was added. The cell suspension was
transferred to the Nucleocuvette vessels and the program FF-
100 was executed on the 4D Nucleofector. 500 µl of pre-warmed
THP-1 medium was then added and the cell suspension was
transfered to a 12-well plate with 1 ml of THP-1 medium already
in each well. Next day (∼24 h after nucleofection), the cells were
spun down at 400 g for 5 min at room temperature, and the
pellet resuspended in 300 µl of 10% fetal bovine serum in PBS
and subjected to flow cytometry assisted cell sorting. Single GFP
positive cells (which had taken up the plasmid) were sorted into
96-well plates with 200 µl THP-1 media per well, using a BD
FACS Aria IIIu (BD Biosciences, San Jose, CA, United States).
Validation of Knockout Cell Lines
The single cell clones were left to grow in 96 well plates until
there were enough cells to passage into a bigger vessel (multiple
weeks). DNA was prepared from these potential knockout
clones using phenol extraction. DNA was resuspended using a
suitable volume of TE or water. The targeted region was then
amplified by the polymerase chain reaction using High Fidelity
Q5 Polymerase (NEB) according to manufacturer’s instructions.
The primer sequences were CCTAGCGAGTGCATGGTTTT
(USP16 CRISPR site F) and ACCCAAGAGGCAGAGGAACT
(USP16 CRISPR site R) and the Tm for both was 65◦C (NEB
Tm Calculator7). The samples were initially denatured at 98◦C
for 30 s, then incubated for 35 cycles of 98◦C for 10 s, 65◦C
for 30 s and 72◦C for 30 s. The final extension was at 72◦C
for 2 mins. The PCR product was run on a 1.5% agarose gel
(Agarose Ultrapure, Invitrogen, Paisley, United Kingdom) in 1X
TAE with 1X of SYBR Safe DNA stain (Invitrogen). 20 µl of
the PCR product was purified using Charge Switch PCR clean-
up kit (Invitrogen) according to manufacturer’s instructions. For
sequencing, 3 µl of water, 2 µl of the purified PCR product
and 1 µl of 3.2 µM primer was mixed and sent for chain
termination (Sanger) sequencing at Edinburgh Genomics. The
results were viewed using FinchTV programme (Geospiza, Perkin
Elmer, Waltham, MA, United States) or Chromas8.
Gene Expression Analysis
RNA was extracted from pelleted cells using RNABee (AMS
Biosciences, Friendswood, TX, United States) or TRIzol (Thermo
Fisher Scientific, Waltham, MA, United States) according to
the manufacturers’ instructions. The RNA samples were then
treated with DNase I according to manufacturer’s instructions
7http://tmcalculator.neb.com
8https://technelysium.com.au/wp/chromas/
(Ambion DNase kit AM1906, Thermo Fisher Scientific). The
concentration of RNA was measured using a NanoDrop
spectrophotometer ND-1000 (Nanodrop Technologies,
Wilmington, DE, United States) and quality was assessed using
the Agilent RNA ScreenTape System (Agilent Technologies,
Santa Clara, CA, United States) according to the manufacturer’s
instructions. 500 ng DNase I treated RNA was used to prepare
cDNA, together with 2 µl random primers (50 ng/µl, Invitrogen)
and 1 µl dNTPs (10 mM, Invitrogen), with water to 13 µl. The
RNA with random primers was denatured at 65◦C for 5 mins
and then cooled at 4◦C for at least 1 min. Afterward, 4 µl 5x
first strand buffer (Invitrogen), 1 µl 0.1 M DTT (Invitrogen),
1 µl RNAsin Plus (Promega, Madison, WI, United States) and
1 µl Superscript III Reverse Transcriptase (RT; Invitrogen) were
added to the mixture. An RT negative control was prepared
using RNAse-free water instead of RT. The cDNA synthesis
reaction was incubated at 25◦C for 5 mins, 50◦C for 60 mins, and
finally 70◦C for 15 mins to stop the reaction. Before quantitative
polymerase chain reaction (qPCR), the cDNA was diluted 1:1
with 20 µl water. To establish standard curves, cDNA from
THP-1 RNA was diluted three times. The first point of the
standard curve was undiluted cDNA (estimated 12.5 ng/µl),
then 1:1 (estimated 6.25 ng/µl), then 1:4 (estimated 3.125 ng/µl),
and 1:8 (estimated 1.5625 ng/µl). qPCR was used to assess
the levels of USP16 expression using manufacturer’s protocols
for SYBR Green 1 Master Mix with Light Cycler 480 96-well
white plates (Roche, Mannheim, Germany). The settings for
all qPCR analyses (both quantification and melting curves for
primers) were as follows: pre-incubation was carried out at
95◦C for 5 mins (ramp rate 4.40◦C/s), then amplification steps
were repeated for 45 cycles. Amplification steps were as follows:
95◦C for 10 s (ramp rate 4.40◦C/s), 60◦C for 15 s (ramp rate
2.20◦C/s), and 70◦C for 30 s (ramp rate 4.40◦C/s). Afterward,
the melting curve was measured by incubating at 95◦C for 5 s
(ramp rate 4.40◦C/s), 65◦C for 1 min (ramp rate 2.20◦C/s)
and then the temperature was increased to 97◦C by 0.11C◦/s.
At the end, the plate was cooled for 30 s at 40◦C. All reverse
transcriptase-qPCR analysis was carried out using the Advanced
Quantification setting of the Light Cycler 480 Roche software.
1Ct was calculated with previously established values of primer
efficiencies from standard curves (calculated using the same
software, by using Abs Quant/2nd Derivative Max setting).
Two sets of primers for two different housekeeping genes were
used in this study. The first one was for the human beta actin
gene (ACTB) (Maess et al., 2010); the second, for GAPDH, was
purchased from Qiagen (QuantiTect Primer Assay QT0112646).
The USP16 primers were designed to span an intron, to have
melting temperature (Tm) of 60◦C and to generate a cDNA
product of approximately 200 bp, using Primer3 program9. The
ideal slope value from standard curves is around −3.345 when
the primer efficiency is 2, but values from −3.0 to −3.5 were
considered acceptable (Table 1).
CAGE (Cap Analysis Gene Expression)
Cap analysis gene expression libraries were made as described
previously (Takahashi et al., 2012; Gazova et al., 2020). Libraries
9http://primer3.ut.ee/
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TABLE 1 | qPCR primers and efficiencies for USP16 expression analysis.










were sequenced by Edinburgh Genomics on an Illumina
HiSeq 2500 machine in high throughput mode. One library
consisting of eight pooled samples was sequenced per lane,
with custom sequencing primer and inline barcodes. Quality
control, quantification of expression levels and bioinformatic
analysis were performed as described (Gazova et al., 2020).
The final expression value for each CTSS (CAGE transcription
start site) was provided as TPM (tags per million). The
normalized data were then formatted into OSCtable10, providing
chromosome, start, end and strand coordinates and uploaded
into ZENBU11 (Severin et al., 2014). CTSS were clustered in
each sample based on their distance apart using distclu option
in CAGEr package (Haberle et al., 2015). The settings were as
follows, the minimum CTSS TPM value was 1, the distance
between CTSS was maximum of 20 bp and singletons (single
CTSS not neighboring any other CTSS) were not removed.
To compare the clustered CTSS across different samples, the
CTSS range values were aggregated, retaining only the CTSS
clusters with expression in at least one sample of higher than
5 TPM. The maximum distance between CTSS was kept at
100 bp. These commands created a single matrix file with
cluster coordinates (start, end, strand) and normalized TPM
values for the aggregated clusters. Normalized and annotated
clusters of CTSS were allocated to the nearest downstream
gene (Gazova et al., 2020). A matrix of gene annotations
and expression values was uploaded into BioLayout software
(Freeman et al., 2007; Theocharidis et al., 2009)12. Sample-to-
sample correlation (equivalent to principal components analysis)
was created by transposing the data in pre-processing and
analyzed at a Pearson correlation coefficient (r) threshold of
0.88. Gene network analysis created a graph by visualizing
each node as one aggregated cluster of CTSS. A correlation
graph was created at r ≥ 0.92 (Supplementary Figure 1) using
Fast Multiple Multilevel Method (FMMM) format. The analysis
was done by clustering using the Markov Cluster Algorithm
(MCL) at inflation values indicated in the Results section.
Differential gene expression was analyzed using the edge package
for the R statistical environment13. GO enrichment analysis





Evolutionary Relationships, release of July 28, 2020; available
through The Gene Ontology Resource14). The background was
Homo sapiens, the test used was Fisher’s Exact test and all results
were corrected for multiple testing using the Bonferroni method.
Western Blot
For each sample, 2 × 106 cells were resuspended in 50 µl
PBS, then 50 µl of 2X Laemmli loading buffer with 50 mM
DTT (BioRAD, Hercules, CA, United States, prepared by mixing
950 µl Laemmli loading buffer + 50 µl 1M DTT (NEB) in
water) was added and mixed thoroughly. Samples were then
incubated at 95◦C for 5 mins and stored at −20◦C until needed.
Samples were loaded on a precast Mini-Protean TGX 4-15% 12-
well gel (Bio-Rad Laboratories, Herclues, CA, United States).
A molecular weight marker (PageRuler Plus Prestained Protein
Ladder, Thermo Fisher Scientific) was loaded in the outer lanes.
The running buffer was 25 mM Tris (Thermo Fisher Scientific),
192 mM Glycine (Sigma-Aldrich) and 0.1% w/v SDS (Thermo
Fisher Scientific) and the gel was run at 100V for 5 min and
then 120V till the end of the gel. The gel was then rinsed in
water. The protein was then transferred onto PVDF membrane
(Immobilon-P, Sigma-Aldrich, St Louis, MO, United States),
using a Bio-Rad transfer apparatus, according to manufacturers’
instructions. The blotting was run at 50 V for 1 h at initial
current of 400 mA. The membrane was blocked for 1 h in 5%
milk powder (Marvel Dried Milk, Premier Foods Group Ltd.,
London, United Kingdom) in PBS-T (0.05% Tween in PBS).
Primary anti-human antibodies (dilution of 1:1000 for rabbit
anti-USP16 (ab121650, Abcam, Cambridge, United Kingdom);
and 1:2000 dilution for mouse anti-ß-actin (C4) monoclonal
IgG1 (sc-47778, Santa Cruz Biotech, Dallas, TX, United States)
were diluted in 5% milk powder in PBS-T and the membrane
immersed rotating overnight at room temperature. The next day,
the membrane was washed six times for 5 min in PBS-T, and
then secondary antibodies were diluted at 1:2000 in 5% milk
powder in PBS-T (horse anti-mouse HRP-linked for β-actin and
goat anti-rabbit HPR-linked for USP16; both from Cell Signaling
Technology, Danvers, MA, United States), and the membrane
immersed rotating for 1 h at room temperature. The membrane
was again washed six times for 5 min in PBS-T, and then Pierce
ECL western blotting substrate (Thermo Fisher Scientific) was
applied according to manufacturer’s instructions. The image was
developed onto Amersham Hyperfilm (GE Healthcare, Little
Chalfont, United Kingdom).
Analysis of Edited Cells
MTT assay was performed to assess metabolic activity and cell
proliferation. A 96-well plate was seeded with 2 × 104 THP-
1 cells in 100 µl of media per well. After 48 h, 10 µl MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
5 mg/ml, Sigma Aldrich) was added to each well and incubated
for 3 h at 37◦C in 5% CO2. Then 100 µl solubilization solution
(89% (v/v) Isopropanol, 10% (v/v) Triton 100x, 1% (v/v) HCl)
was added and left at 37◦C 5% CO2 overnight. The following
day, substrate conversion was determined via the optical densities
14http://geneontology.org/, Go Ontology database DOI: 10.5281/zenodo.4081749
Released 9 October 2020
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which were measured using a plate reader at 570 nm. The
phases of the cell cycle were determined using propidium iodide
staining, as described previously (Gazova et al., 2020).
A phagocytosis assay was performed by incubating THP-1
macrophages that had been differentiated with PMA for 2 days
with Zymosan A particles (Thermo Fisher Scientific, Z2841)
coated with fluorescein isothiocyanate (FITC), at a ratio of 100
particles per cell; for 1 h at 37◦C. Cells were washed five times
with cold PBS and fixed with 4% paraformaldehyde (PFA, WVR,
Radnor, PA, United States) for 10 min at room temperature and
washed twice with PBS. Images were viewed using a fluorescent
microscope (Zeiss Vert.A.1, Carl Zeiss Limited, Cambridge,
United Kingdom).
Statistical Analysis
Results are presented as mean ± standard error. Significance
of differences was assessed using a two tailed t-test where two
groups were compared or a two tailed Z-test where a single
sample was compared with the mean of multiple values.
RESULTS
Editing of the USP16 Gene in THP-1 Cells
The guide was designed to make an indel in exon 5 of USP16,
creating an out of frame mutation. Exon 5 (the third coding exon)
codes for part of the zinc finger domain. Out of two 96 well
plates, 15 clones survived the sorting and 3 clones proved to be
heterozygous for the same single nucleotide insertion (adenine)
into the expected site. The sequence is shown in Figure 1B. No
homozygotes were present at the first targeting, so two of the
heterozygotes were used for targeting a second time with the same
guide. Out of 3 plates for each heterozygous parental cell line, 67
clones survived the sorting. 13 clones (19%) had reverted to the
wild type sequence and 4 clones (6%) were homozygous for the
same adenine insertion in exon 5 (Figure 1B). The insertion site
of the adenine in exon 5 created a frame shift, with an in-frame
stop codon ten amino acids downstream. Any resulting peptide
would be small and contain only the start of the protein sequence
with no functional domains (Figure 1C). One homozygous clone
(Hom1) was derived from one heterozygote (HetC) and the other
three (Hom2, Hom3, and Hom4) from a second heterozygote.
Sequencing of the cDNA derived from the homozygous clones
confirmed that the insertion was present in the transcript as well
as the gene (not shown).
Impact of USP16 Frame Shift on Gene
Expression
Quantitative reverse transcriptase PCR experiments were
conducted with the four homozygotes, a parental heterozygote
(HetC), a heterozygote from the second targeting (HetdE) and
wild type THP-1 cells for 3 sets of primers, each amplifying a
different exon along the transcript (Table 1). Consistent with
predicted nonsense-mediated decay, the USP16 −/− homozygous
clones had decreased level of mRNA compared to wild type THP-
1 cells (Figure 2A) for all three sets of primers (p < 10−7 for each
set of primers). The USP16 expression levels were also extracted
from the transcriptomic data generated by CAGE analysis (see
below) and found to be negligible in the homozygous edited
clones after differentiation (p = 0.004) (Figure 2B).
The production of USP16 protein in the edited clones
was assessed by western blotting. Previous studies reported
an estimated molecular weight for USP16 of 110 - 120 kDa
(Joo et al., 2007; Xu et al., 2013), although the antibody
manufacturer predicted a band size of 94 kDa. A band of
around 120 kDa was present in heterozygotes and wild type
but absent in the homozygous clones (Figure 2C). There was
no evidence of any bands between 70 and 130 kDa in the
homozygotes. This suggests that the homozygous clones were not
making full length USP16. Other bands on the gel (Figure 2C)
that were not altered in the deleted clones may be from
different deubiquitinases, since there is strong homology in
the family.
Cellular Impact in USP16 Knockout Cells
The USP16 knockout clones retained active proliferation in
the absence of PMA, indicating that USP16 is not absolutely
required for mitosis in these leukemic cells. Upon addition
of PMA the parent THP-1 USP16+/+ high differentiation
clone underwent growth arrest, with down-regulation of cell-
cycle associated transcripts and MYB, and up-regulation of
macrophage markers (Gazova et al., 2020). The absence of
functional USP16 did not alter the ability of the cells to
undergo this differentiation process. In control and USP16-
deficient cells, addition of PMA generated a confluent layer
of adherent macrophage-like cells after 48 h. These cells were
able to phagocytose Zymosan A particles and there was no
apparent difference between the control and USP-deficient clones
(Figure 3A).
To analyze the requirement for USP16 in growth regulation of
these cells, we first assessed proliferation based upon metabolic
activity (MTT reduction). This was assessed on both early and
late passage lines to determine whether there was any phenotypic
drift. The results differed among USP16−/− homozygotes.
The proliferative activity of wild type, heterozygotes and
homozygote Hom1 was indistinguishable, as indicated by the
level of metabolic activity after 48 h in culture. The remaining
homozygotes (Hom2, Hom3, and Hom4, all derived from
the same heterozygote) were also actively proliferative albeit
with a marginal decrease in MTT reduction compared to
WT (Figure 3B).
To assess the impact of USP16 mutation on cell cycle
regulation, the various clones were differentiated into
macrophages with PMA over the course of 3 days and the
proportions of cells in different phases of the cell cycle were
assayed each day using propidium iodide staining and flow
cytometry. This analysis confirmed that USP16 is not absolutely
required for cell cycle progression. Before differentiation, edited
and wild type cells were indistinguishable, with 20-30% of cells in
S phase (Figure 3C). During differentiation of THP-1 USP16+/+
monocytes to macrophages in response to PMA the proportion
of cells in S phase was previously shown to decline as the cells
differentiate (Gazova et al., 2020). This response was replicated
here in wild type and in USP16 heterozygous and homozygous
cells, although the decline in Hom2 was not as marked. The
proportion of cells in S phase was reduced to half or less in most
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FIGURE 2 | USP16 expression in edited clones. (A) Quantitative PCR for three sets of USP16 primers, targeting different exons. RNA was from undifferentiated
cells. Blue – wild type; purple – heterozygotes; red – homozygotes. Y-axis shows the Roche ratio normalized by ACTB expression with error rates calculated by
Roche LightCycler480 software. Error bars show standard error. Asterisk shows technical failure of qPCR for HetdE. All assays were carried out in duplicate.
Homozygotes were significantly different from wild type (all p < 10−7); heterozygotes were not significantly different from wild type. (B) USP16 expression derived
from transcriptomic analysis using CAGE. Expression levels are shown for control untreated cells (darker columns) and cells after 24 h of PMA stimulation (lighter
columns). Blue – wild type; purple – heterozygotes; values in homozygotes were all 0. Homozygotes were significantly different from wild type (p = 0.03 at 0 h and
p = 0.004 at 24 h). Heterozygotes were not significantly different from wild type at either time point. (C) Western blotting for USP16 and actin in extracts of THP-1
clones. Lanes 1, 2, 3, and 4 are USP16 knockout homozygotes; lanes 6 and 7 are USP16 knockout heterozygotes, and lane 8 shows the wild type THP-1 cell line.
Molecular weight ladder sizes (kDa) are shown to the right of the image. Actin loading control bands of 42 kDa are indicated. All other bands were detected by
anti-USP16 antibody (ab121650). Bands of around 120 kDa (present in heterozygotes and wild type) were not present in the four homozygous USP16 knockout
THP-1 clones (arrowhead).
lines alongside an increased proportion in G1 phase by Day
2. In Hom2, the proportion of cells in S phase following PMA
treatment was maintained around 30% (Figure 3C). As indicated
by the error bars in Figure 3C, there was considerable variability
between replicates.
Transcriptomic Analysis of Wild Type
THP-1 and USP16 Knockout Clones
The phenotypic analysis indicated that the impact of the USP16
insertion is conditional; in one clone (Hom2) there was a reduced
impact on proliferation though not on differentiation, whereas
Hom1 was not different from its heterozygous parent HetC or
the replicates from the original wild type THP-1 clone. To dissect
the reasons for this variable impact, RNA from USP16 knockout
THP-1 cells was subjected to expression analysis using CAGE
before and after 24 h PMA stimulation, and compared with
results for wild type using CAGE sequencing results from the
0 and 24 h time points of the previous publication (Gazova
et al., 2020). Sample-to-sample analysis (which provides similar
information to a principal components analysis) using BioLayout
network analysis software showed that prior to PMA treatment,
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FIGURE 3 | Impact of USP16 knockout on cellular functions. (A) Phagocytosis of Zymosan particles by wild type and edited clones. Adherent THP-1 cells
differentiated with PMA were incubated with FITC-labeled Zymosan particles for 1 h at 37◦C and washed as described in Methods. Images show that the large
majority of cells in each culture contained labeled (green) particles. (B) Proliferation of individual THP-1 clones measured using the MTT reduction assay. Cells were
plated at 2 × 105/ml and incubated for 48 h, prior to assay of viable cells as described in Methods section. Dark colors show an assay after initial expansion; light
colors show a repeat assay of the same clones, after several passages. Y-axis shows the optical density after 48 h. Red – homozygotes; purple – heterozygotes;
blue – wild type. HetD was only tested after the initial expansion and HetC was only tested after several passages. (C) Proportion of cells in different stages of the cell
cycle in wild type and edited clones. Cell cycle was analyzed by flow cytometry of propidium iodide-stained cells as described in Methods. Results are the average of
3 (HetC) or 4 experiments. Upper panel – before differentiation; lower panel – after 2 days with PMA. Blue – G1 phase; orange – S phase; green – G2 phase. Error
bars show standard error.
all cells had similar transcriptomic profiles (dark green in
Figure 4A). All cell lines showed some change over the first
24 h of differentiation, with the transcriptome of the wild type
cells changing most and Hom4 changing least (Figure 4B).
One heterozygote (HetC) was similar to wild type and the
other (HetdE, a heterozygous clone that had been through two
rounds of targeting, from the same parent as Hom2, Hom3,
and Hom4) was similar to the homozygotes, which were closest
to undifferentiated cells in the network, indicating a reduced
response to PMA (Figure 4B).
The differentiation of THP-1 cells is associated with up-
regulation of a number of macrophage-specific genes, including
CSF1R, which encodes the receptor for the lineage-specific
growth factors CSF1 and IL34 (Hume et al., 2016; Gazova et al.,
2020). The three related homozygous knockout lines (Hom2,
Hom3, and Hom4) showed no increase of CSF1R mRNA after
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FIGURE 4 | Sample to sample network graph of edited clones. Circles represent clones and lines between them correlations of at least 0.88. Wild type results are
from Gazova et al. (2020). (A) Analysis showing the transition from 0 h (dark green) to 24 h post PMA treatment (light green). (B) The same network as in panel (A),
colored to show the effect of genotype on the transition following PMA treatment. Dark colors show cells prior to treatment, light colors show cells 24 h after PMA
treatment. Red – homozygotes; purple – heterozygotes; blue – wild type.
PMA treatment (p = 0.19; Figure 5A), while their double targeted
“sibling” HetdE showed a small (3-fold) increase. In contrast,
Hom1 and its parental heterozygote HetC showed approximately
10-fold increase in CSF1R, greater than the 5-fold increase seen
in wild type. The progenitor cell marker MYB decreased to
about 15% in wild type after PMA treatment. This marker was
higher in Hom1 and HetC than in wild type prior to treatment
and decreased to less than 15% 1 day after PMA treatment.
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FIGURE 5 | Expression of signature genes in edited clones. Results are based on expression levels extracted from CAGE data. Wild type samples are from Gazova
et al. (2020); results are the mean of 6 (0 time point) and 4 (24 h time point) replicates and standard error is shown by the bars. (A) Expression of CSF1R (total of three
promoters), a marker of monocyte to macrophage transition. At 0 h, Hom1 was significantly lower than wild type (p = 0.0006) while at 24 h it was significantly higher
(p = 0.01). The mean value for Hom2-4 was slightly higher than wild type at 0 h (p = 0.04) but did not change after PMA stimulation and was then significantly lower
than wild type (p = 0.005). (B) Expression of MYB (total of two promoters), a marker of cell proliferation. At 0 h, Hom1 was significantly higher than wild type (p = 0)
while at 24 h it was not significantly different (p = 0.15). The mean value for Hom2-4 was slightly higher than wild type at both 0 and 24 h (p = 0.04 in both cases).
In the double targeted HetdE, Myb expression prior to PMA
treatment was similar to HetC, but only decreased to about 40%.
In Hom2, Hom3 and Hom4, MYB expression was lower prior
to differentiation and dropped up to 50% after PMA treatment
(p = 0.03) indicating that cell proliferation persisted in these
clones (Figure 5B).
To explain the apparent redundancy of USP16 for cell
proliferation and differentiation, and inconsistency between
the mutant clones, we examined expression of other histone
deubiquitinase genes. Because Hom1 was different from the other
homozygotes, it was analyzed separately. All homozygotes had
higher levels of expression prior to differentiation for USP12,
BAP1, and MYSM1 (Figure 6 and Table 2). USP12 and MYSM1
were induced in wild type cells upon PMA treatment, reaching
the same level as the homozygotes. BAP1 did not change
following PMA treatment and was significantly elevated in Hom1
regardless of time point. Hom1 was also higher than wild type for
USP21 both before and after treatment but lower than wild type
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FIGURE 6 | Expression of deubiquitinase genes in edited clones. Results are based on expression levels extracted from CAGE data. Wild type samples are from
Gazova et al. (2020). Results for wild type are the mean of 6 (0 h time point) and 4 (24 h time point) replicates. Results for Hom2, Hom3, and Hom4 were averaged.
Standard error is shown by the bars. Significance of differences between genotypes can be seen in Table 2. (A) Expression of USP3. (B) Expression of USP12.
(C) Expression of USP21. (D) Expression of USP22. (E) Expression of USP46. (F) Expression of BAP1. (G) Expression of MYSM1.
for USP22 prior to treatment (Figure 6 and Table 2). Expression
of USP3 in Hom2, Hom3, and Hom4 was lower than wild type
after 24 h of PMA treatment, suggesting that these clones failed
to fully induce USP3 during differentiation. There was no effect
of the USP16 knockout on USP46, which had relatively low
expression in these cells.
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TABLE 2 | Expression of deubiquitinases in USP16 edited cells.
Gene Time point Wild type Hom 1 Hom 2–4 All homozygotes P (Hom 1 vs.
wild type) (2-tailed
Z-test)
P (Hom 2–4 vs.





USP3 Day 0 7.40 ± 1.66 6.42 8.78 ± 0.71 8.19 ± 0.78 0.56 0.47 0.68
Day 1 20.08 ± 1.14 17.98 12.99 ± 0.16 14.23 ± 1.25 0.07 0.008 0.01
USP12 Day 0 28.50 ± 5.27 65.80 50.29 ± 5.75 54.17 ± 5.62 1.53E–12 0.04 0.01
Day 1 62.96 ± 7.84 63.96 51.33 ± 2.81 54.49 ± 3.73 0.90 0.24 0.38
USP21 Day 0 17.78 ± 1.89 42.68 24.73 ± 2.14 29.22 ± 4.74 0 0.06 0.09
Day 1 22.65 ± 1.92 34.43 25.85 ± 2.39 28.00 ± 2.73 9.33E–10 0.35 0.17
USP22 Day 0 93.16 ± 6.95 67.78 79.80 ± 5.83 76.80 ± 5.10 2.62E–4 0.19 0.09
Day 1 82.15 ± 8.37 67.74 63.93 ± 5.47 64.88 ± 3.98 0.09 0.13 0.13
USP46 Day 0 5.38 ± 0.76 5.10 5.50 ± 0.61 5.40 ± 0.44 0.71 0.91 0.99
Day 1 3.83 ± 0.31 3.60 4.40 ± 0.82 4.20 ± 0.61 0.47 0.56 0.61
BAP1 Day 0 9.31 ± 0.62 24.84 20.37 ± 0.92 21.49 ± 1.29 0 6.45E–04 6.90E–04
Day 1 9.84 ± 2.32 18.63 15.88 ± 2.80 16.57 ± 2.10 1.52E–4 0.17 0.08
MYSM1 Day 0 40.41 ± 5.93 55.91 59.49 ± 3.55 58.59 ± 2.67 8.89E–3 0.03 0.03
Day 1 66.55 ± 7.45 61.59 64.66 ± 3.10 63.89 ± 2.32 0.50 0.83 0.75
Data were taken from expression levels derived from CAGE analysis. Results for homozygotes are a single replicate for Hom1 and the average of the three lines for Hom2,
Hom3, and Hom4. Results for wild type are the average of six experiments for day 0 and four experiments for day 1. Results are shown as mean ± standard error. Cells
are colored by significance level: deep orange P ≤ 0.001; mid orange 0.001 < P ≤ 0.01; light orange 0.01 < P ≤ 0.05. Two-tailed tests were used.
Network Analysis of USP16 Edited
Clones
The analysis of differentially expressed genes and determination
of the phenotypes of the edited clones indicated that there
were impacts of the lack of USP16 in both homozygotes and
heterozygotes, and that the edited lines had adapted to the
knockout in different ways. To dissect the differences further,
the CAGE-based transcriptional profiles of the USP16 knockout
homozygous, heterozygous and wild type clones were analyzed
using BioLayout network analysis software. A gene-to-gene
analysis was performed with a relatively stringent Pearson
correlation coefficient threshold of 0.92 and MCL clustering with
an inflation coefficient of 2.0 (Figure 7A). This included 5640
nodes (representing CTSS, equivalent to gene promoters) making
109,930 edges (correlation of at least 0.92 between nodes). The
majority of the nodes (4474 nodes, 105,618 edges) were in two
distinct regions, which were associated with high expression
either in THP-1 cells prior to treatment with PMA (monocytic
cells), or in THP-1 cells after 24 h treatment (macrophage-like
cells) (Figure 7A). The remaining nodes were in smaller elements
of 2 to 154 nodes. Cluster lists for clusters discussed below are
available in Supplementary Figure 2 and show groups of genes
whose expression patterns were more similar to each other than
to others in the analysis, as identified by the MCL clustering
method. The largest cluster was Cluster 1 with 850 nodes (CTSS),
which included the main CSF1R promoter and contained genes
which were upregulated after differentiation (Figure 7B). Genes
in this and other smaller clusters showing high expression
24 h after induction of differentiation tended to be associated
with immunity, cell-cell adhesion and migration, neutrophil
degranulation and the lysosome (analyzed by PANTHER – see
Supplementary Figure 2), although there was a wide variety of
GO terms found for these genes. The second most abundant
cluster was Cluster 2 with 286 nodes, which contained genes
highly expressed in monocytic THP-1 cells prior to differentiation
(Figure 7B). A number of smaller clusters also showed this
pattern and contained genes associated with cell division, the cell
cycle and DNA replication and repair (Giotti et al., 2019). Notably
cluster 6 (80 nodes) showed this pattern and contained the
majority of the detected histone genes. There was little indication
of an effect of absence of functional USP16 on genes in these
clusters, showing that homozygous and heterozygous USP16
knockout cells maintain most of the gene expression patterns of
monocyte and macrophage-like wild type cells, consistent with
the ability to phagocytose and differentiate shown above.
To understand how the edited clones are able to maintain
these functions, we looked for clusters where the expression
pattern was different from wild type. As we have seen previously
for cell lines (Gazova et al., 2020) and inbred animals (Summers
et al., 2020), there was considerable variation among replicates,
reflected in clusters with idiosyncratic profiles usually dependent
on a single sample (shown in Supplementary Table 1). The wild
type replicates were all generated from the parent THP-1 clone
5, so these differences may reflect phenotypic drift or phenotypic
heterogeneity of the parent clone. The edited samples represent
different clonal lines, each of which may have responded to the
effect of the knockout differently. In particular, Hom1 and its
parental heterozygote HetC showed a different phenotype from
the other heterozygote and homozygotes (Figures 3, 5). However,
there were several clusters where there was a clear difference
between the wild type replicates and the edited clones, enabling
some insight into the mechanisms used by the cells to escape the
effects of the absence of USP16.
Genes in Cluster 13 (38 nodes), Cluster 31 (15 nodes),
Cluster 37 (13 nodes) and Cluster 44 (12 nodes) were high
in most wild type replicates prior to PMA stimulation. These
genes were low in wild type after 24 h of PMA treatment and
low in all heterozygous and homozygous clones at both time
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FIGURE 7 | Network analysis of edited cells. (A) Gene-to-gene 2D network graph. Image taken from BioLayout output showing CTSS-CTSS correlations
(nodes = CTSS; edges = correlations of ≥0.92 between them). The analysis included all four USP16 knockout lines, HetC and HetdE and wild type samples; raw
data for wild type are from (Gazova et al., 2020), 0 h and 24 h time points. Nodes in the same cluster have the same color. (B) Average expression profiles for
Clusters 1 and 2, showing up- or down-regulation in response to PMA in all cells. (C) Average expression profiles for Clusters 4 and 11 showing very small effect of
PMA in the edited homozygous and heterozygous cells. (D) Average expression profiles for Clusters 10 and 19, showing specific expression in Hom1 and its parent
HetC at 0 h (cluster 19) or 24 h post PMA treatment (Cluster 10). (E) Average expression profiles for Clusters 15, 16, and 24 showing expression in some or all wild
type samples as well as HetC and Hom1. (F) Average expression profile for Cluster 42, showing high expression only in HetdE, Hom2, Hom3, and Hom4. In panels
(B-F), Y-axis shows the average expression of genes in the cluster in TPM. X-axis shows the samples. The bar along the X axis shows the time point, colored as for
Figure 5: dark colors 0 h, light colors – 24 h after PMA stimulation; blue – wild type, purple – heterozygotes, red – homozygotes. Samples are in the order wild type
(6 samples at 0 h and 4 at 24 h), heterozygotes (HetC, HetdE), homozygotes (Hom1, Hom2, Hom3, and Hom4). Columns have the same color as the clustered
nodes in panel (A).
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points. Because of the small number of genes in the clusters,
GO enrichment analysis was performed on the combined list of
genes to increase the power. With Bonferroni correction, the only
enriched terms were GO Cellular Component (GO CC) terms
relating to the mitochondrial matrix. For ontology terms, the
Bonferroni adjustment is considered conservative since the terms
are not independent (PANTHER documentation15). Therefore
we used a reduced stringency (raw P-value < 0.001) to look
for possible enrichment. GO Biological Process (GO BP) terms
relating to metabolic processes and mitochondrial functions were
enriched at this level (Supplementary Table 2). In contrast,
genes in Cluster 33 (14 nodes) were low in wild type prior to
PMA stimulation and increased in wild type after treatment and
were high in all homozygotes and heterozygotes at both time
points. This group was too small for meaningful GO enrichment
analysis. These clusters indicate genes which may be affected by
the absence of USP16, either in the monocyte state or after the
cells are triggered to differentiate. Notably, the group which is
low in the edited clones contains the SRPRB gene (Cluster 13),
which encodes a protein thought to be an interaction partner
of USP16 (BioGRID database of protein, genetic and chemical
interactions16).
There were several other clusters which contained genes that
were differently expressed in wild type and the edited clones.
The average expression of genes in Cluster 4 (140 nodes) was
up-regulated 8 to 30-fold during differentiation of wild type THP-
1 cells (Figure 7C) but only increased up to two-fold in the
heterozygous and homozygous knockout clones. These genes are
likely dependent on USP16 for expression. This cluster contained
known interferon inducible genes, and a promoter for the gene
encoding the key transcription factor IRF9. GO annotations for
genes within this clusters were enriched for terms involved with
interferon signaling and response to virus.
Cluster 11 (44 nodes) contained genes that were increased 6
to 8 fold in wild type 24 h after PMA treatment. These genes
were also increased at 24 h in heterozygotes and homozygotes,
but only 4- to 5-fold (HetC and Hom1) or 2- to 3-fold (HetdE
and Homs 2-4) (Figure 7C). These genes appear to be impacted
by the loss of USP16, even in the heterozygotes which had wild
type levels of expression of USP16 mRNA (Figure 2). There
was no significant GO term enrichment for these genes using
the stringent Bonferroni correction. As above, to gain further
insight into the impact of USP16 absence, we therefore looked
at GO terms using a less stringent uncorrected significance
threshold of P < 0.001. At this significance threshold, enriched
GO Biological Process (GO BP) terms were related to regulation
of immune system processes and membrane transporter activity
(Supplementary Table 2).
Cluster 19 (23 nodes) contained genes that were high only
in HetC and Hom1 prior to PMA treatment (Figure 7D).
Although there were no significant GO terms for this small
cluster using the Bonferroni correction, genes included several
involved in the cell cycle (BUB1, ESPL1B, and FANCA) (Giotti
et al., 2019). This was reflected in the GO BP terms enriched at
15pantherdb.org/tips/tips_bonferroni.jsp, accessed February 2021
16https://thebiogrid.org, accessed February 2021
lower stringency (uncorrected P < 0.001) which included terms
relating to chromosome separation (Supplementary Table 2). In
all cases of genes with multiple promoters, a minor promoter was
found in this cluster, suggesting that one way Hom1 escapes the
lack of USP16 and maintains the ability to proliferate (shown by
the high level of MYB seen in Figure 5B) is to up-regulate minor
promoters of other genes to compensate.
Cluster 10 (52 nodes) was the reciprocal of Cluster 19, where
average expression increased around 5-fold in most samples at
24 h, but in HetC and Hom1 these genes were increased 27-
and 53-fold respectively (Figure 7D). Most promoters in this
cluster were expressed only in these two samples. As for Cluster
19, where genes had more than one promoter in the analysis,
promoters in this cluster were almost all minor (usually low
expression) promoters, including the third promoter for CSF1R.
There was no GO terms enrichment at the stringent Bonferroni
corrected significance level, but there was enrichment for genes
associated with the PANTHER integrin signaling pathway. To
examine the adaptations of HetC and Hom1 we therefore
looked at GO terms using an uncorrected significance threshold
of P < 0.001, which showed enrichment for GO BP terms
related to tumor necrosis factor production, negative regulation
of cell death, positive regulation of macrophage proliferation,
cytokine production, regulation of histone phosphorylation and
morphogenesis (Supplementary Table 2).
Several other clusters contained genes that were up-regulated
in at least some wild type samples and in HetC and Hom1 at
24 h. Genes in Cluster 15 (29 nodes) were up-regulated after PMA
stimulation in three wild type samples and in Hom1 and HetC
(Figure 7E). The cluster included the gene for CSF1, the major
effector of macrophage differentiation. Cluster 16 genes were also
up-regulated at 24 h in wild type, HetC and Hom1 (Figure 7E).
Genes in Cluster24 were increased in two wild type samples at
24 h and to a lesser extent in HetC and Hom1 but not in the other
homozygous and heterozygous cells (Figure 7E). GO enrichment
analysis of the combined gene list from these clusters included
terms related to mesodermal cell differentiation, inflammation
and cell motility.
Since their phenotype showed greater difference to wild
type, and their differentiation appeared less complete than
Hom1 (Figures 3, 5), we also looked for clusters of genes that
distinguished Hom2, Hom3 and Hom4 and the double-edited
HetdE (from the same parent heterozygote) from wild type and
HetC/Hom1. One small cluster (Cluster 42, 12 nodes; Figure 7F)
contained genes that were increased in these cells prior to
differentiation and slightly increased after 24 h with PMA. At
the reduced stringency, enriched GO terms were related to
biosynthetic processes and activation of plasma proteins involved
in acute inflammation. However the major effects on these cells
appeared to be reduction in expression of genes whose levels were
maintained in HetC and Hom1.
DISCUSSION
This paper describes the impact of generating a homozygous
inactivating mutation of the USP16 gene in a high differentiation
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clone of the THP-1 acute monocytic leukemia cell line, using
the CRISPR-Cas9 genome editing technique. The fact that we
generated independent subclonal lines that proliferated in culture
and were able to differentiate in response to PMA might imply
that the many functions attributed to USP16 described in the
introduction are redundant. However, our detailed analysis
rather points to the ability of the leukemic line to adapt to the
extreme selection pressure applied by the loss of USP16 through
different compensatory pathways.
The generation of homozygous USP16 knockout cells required
two rounds of CRISPR-Cas9 mutagenesis. There were no
homozygotes after the first round. After a second round using
heterozygotes from the first round, 4 out of 67 viable clones
were homozygous mutants, whereas 13 reverted back to wild
type, presumably by homology-directed repair from the wild-
type allele. This pattern strongly suggests that the survival
and growth of homozygous USP16−/− cells was compromised,
consistent with the observation that Usp16 knockout is
embryonic lethal in mice (Yang et al., 2014). The THP-
1 USP16−/− survivors had likely up-regulated compensatory
mechanisms (genetic or epigenetic) to overcome the deficiency.
Since the surviving homozygotes had different phenotypes,
depending on the heterozygote from which they originated,
we conclude that different mechanisms were responsible for
the viability of these clones. Aside from the loss of USP16,
additional selection pressures derived from the harsh conditions
of electroporation, FACS sorting and single cell cloning. For
this reason, it is important to use controls that have also
been subjected to the same process. We present results
from heterozygote cells that had been through the same two
rounds of CRISPR-Cas9 treatment. We also assessed doubly
targeted cells which had reverted to wild type, for cell cycle
characteristics; they showed no difference from the parental
wild type cells.
Arguably, selection pressures similar to those of CRISPR-Cas9
treated cultures occur during the evolution of a cancer in vivo
(Fortunato et al., 2017). Although our starting population was
a clonal line selected for high differentiation potential (Suzuki
et al., 2009), THP-1 cells have deficient mutation repair (Bauer
et al., 2011) and the original clonal population is likely by now
to contain divergent lines characterized by different mutations.
The heterozygous mutant lines from the first round may have
been derived from cells that had accumulated other mutations or
epigenetic modifications that compensated at least in part for the
loss of USP16 and allowed the survival of the homozygotes after
the second round of selection.
The simple MTT viable cell assay suggested that three of the
homozygous mutant clones (Hom2, Hom3, and Hom4) grew
marginally more slowly than the parent (Figure 3B) but this
was not supported by cell cycle analysis (Figure 3C). There were
some differences in down-regulation of MYB and up-regulation
of CSF1R between wild type and homozygous clones (Figure 5).
However, in overview the loss of USP16 did not prevent THP-
1 cells from proliferating or differentiating to become adherent
phagocytic macrophages in response to PMA (Figure 3A).
To dissect the transcriptome of THP-1 wild type cells with
the USP16 knockout clones we used CAGE, a promoter based
approach that provides expression levels by capturing mRNA
with the 5′ modified guanine cap (Balwierz et al., 2009; Forrest
et al., 2014). The CAGE data (Figure 2B) confirmed reduction
of USP16 mRNA in the homozygous knockout clones both
before and after PMA treatment, presumably due to nonsense-
mediated decay. Combined with the lack of effect of heterozygous
mutation on USP16 protein (Figure 2C) the data suggest there is
dosage compensation.
The H2AK119 deubiquitinases are collectively involved in
cell cycle progression and DNA repair (Atanassov et al., 2011;
Chen et al., 2015; Aquila and Atanassov, 2020), and the most
obvious potential mechanism to escape the impacts of loss of
USP16 would be to up-regulate related deubiquitinases. Other
studies have observed interdependence of deubiquitinase mRNA
levels. For example, USP12 down-regulation resulted in USP46
up-regulation (Joo et al., 2011). Indeed, mRNA encoding USP12,
BAP1 and MYSM1 was increased in all USP16-deficient lines
and Hom1 also had increased USP21 mRNA, encoding another
H2AK119 deubiquitinase. USP3 and USP22 mRNA showed
distinct patterns of down-regulation by PMA in the different
homozygous lines. Both over- and under-expression of USP3
have been shown to have effects consistent with tumorigenesis.
For example, USP3 promoted proliferation in a number of
cancers (Fang et al., 2018; Wu et al., 2019; Das et al., 2020;
Li et al., 2020; Liao et al., 2020) while other reports show that
depletion of USP3 can increase the incidence of spontaneous
tumors (Lancini et al., 2016), promote metastasis (Wang et al.,
2017), inhibit leukemia cell differentiation (Chae et al., 2019), and
accelerate degradation of TP53 leading to enhanced proliferation
and transformation (Fu et al., 2017).
Our transcriptional network analysis of individual clones in
the presence and absence of PMA complements our recent
high-density time course analysis of the differentiation response
in the parent line (Gazova et al., 2020). In effect it is a
perturbation analysis in which intrinsic plasticity and genetic-
epigenetic instability of THP-1 and clonal heterogeneity, as
well as the specific loss of USP16, all contribute to the
phenotype. Genes in Clusters 4 and 11 were reduced in all
edited cells, both homozygotes and heterozygotes, and were
associated with interferon signaling and immune responses.
Transfection with plasmid DNA to generate mutations activates
the AIM2 inflammasome and cGAS pathways in THP-1 cells
(Burckstummer et al., 2009; Paijo et al., 2016) leading to
interferon induction and inhibition of proliferation as well as
cell death. It is very likely that the generation of mutants selects
against interferon responsiveness. Conversely, other clusters of
genes were greatly increased in the edited cells, albeit not tightly
correlated with USP16 genotype. HetC and Hom1, where the
phenotype was closer to wild type, up-regulated the key regulator,
MYB (Suzuki et al., 2009) which may overcome a partial block on
proliferation caused by the loss of USP16.
Despite the subtle differences in gene expression amongst
the clones, irrespective of the loss of USP16 and the apparent
loss of interferon signaling, all of the lines were able to
undergo macrophage-specific cellular differentiation and some
degree of growth inhibition in response to PMA, indicated
by the coordinated regulation of transcripts within Clusters
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1 and 2 respectively. They each expressed the macrophage-
specific transcription factor SPI1 (encoding PU.1) constitutively
with a similar signal from the upstream enhancer identified
previously (Suzuki et al., 2009; Gazova et al., 2020). The 24 h
time point occurs before induction of surface markers such
as ITGAM (CD11B) and APOE, but the inducible genes in
Cluster 1 include SPP1 (encoding osteopontin) and CSF1R,
both of which were highlighted in earlier analyses (Suzuki
et al., 2009) as well as genes encoding macrophage surface
receptors and lysosomal enzymes. Each clone showed similar
massive induction of the key cell cycle inhibitor, CDKN1A
(p21WAF) highlighted previously (Gazova et al., 2020) and
Cluster 2, down-regulated in all lines, contains numerous
S-phase cell cycle-related transcripts including CDK2, E2F1,
and PCNA.
A limitation of this study is that it used an immortalized
cell line derived from an acute myeloid leukemia 40 years ago.
The compensation phenomenon we have described is specific to
cells under the intense selection of USP16 deletion. Generation
of homozygous knockout clones was a rare event in our study,
with strong selection in the second targeting for cells that had
reverted to wild type. To better understand the role of USP16 and
possible compensatory mechanisms, cells from newly diagnosed
tumors could be examined. In particular, changes in expression of
the histone deubiquitinases over the evolution of the tumor and
during relapses would reveal whether the mechanism proposed
here is also found in primary tumors. There are some examples
of apparent down-regulation of USP16 in cancer (Fernandez
et al., 2004; Gelsi-Boyer et al., 2008; Qian et al., 2016) but USP16
mutation is rare in primary cancers (data from TCGA Project17)
which may be consistent with its important role in the cell cycle
and DNA repair, and a reason why it has been considered as a
cancer drug target. The gene is actually expressed ubiquitously
in every tumor cell line (leukemias, sarcomas, adenocarcinomas)
and proliferating primary cell population that was analyzed in the
large FANTOM5 project (Forrest et al., 2014). A study of those
rare cancers which have inactivating USP16 mutations would
reveal whether the compensatory mechanisms proposed here are
also operating in vivo.
In conclusion, this communication is a case study in leukemic
cell adaptation. The original functional analysis of USP16 (Joo
et al., 2007) reported a 3-fold slowing of proliferation, M phase
arrest and increased basal H2A ubiquitination in HeLa cells with
a stable 90% knock down of the USP16 protein. On that basis
one might consider USP16 as a target for cancer chemotherapy
and indeed that has been proposed (Harrigan et al., 2018). Our
study shows clearly that USP16 is potentially redundant and with
sufficient selection pressure, leukemic cells would give rise to



















The datasets presented in this study can be found in an online
repository at https://www.ebi.ac.uk/ena, PRJEB43087. The results
can be visualised using the ZENBU browser at http://fantom.gsc.
riken.jp/zenbu/gLyphs/#config=Gazova_USP16KO.
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